New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2014
09:06 EDTTKPYYTakeda unit granted orphan status for pancreatic cancer treatment
Millennium Pharmaceuticals' treatment of pancreatic cancer was granted FDA orphan designation, according to a post to the regulator's site. Reference Link
News For TKPYY From The Last 14 Days
Check below for free stories on TKPYY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
07:31 EDTTKPYYEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
September 11, 2014
06:49 EDTTKPYYFDA approves weight management drug Contrave
The U.S. Food and Drug Administration yesterday approved Contrave as treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity. The drug is approved for use in adults with a body mass index of 30 or greater or adults with a BMI of 27 or greater who have at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. Contrave is a combination of two FDA-approved drugs, naltrexone and bupropion, in an extended-release formulation. The effectiveness of Contrave was evaluated in multiple clinical trials that included approximately 4,500 obese and overweight patients with and without significant weight-related conditions treated for one year. Contrave is distributed by Takeda Pharmaceuticals America (TKPYY) for Orexigen Therapeutics (OREX).

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use